Clinical Trials Logo

Clinical Trial Summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.


Clinical Trial Description

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as monotherapy and in combination with other agents as frontline therapy. There are 6 parts of the study. The population to be studied includes treatment-naïve patients with classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell lymphoma (PTCL). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01716806
Study type Interventional
Source Seagen Inc.
Contact
Status Completed
Phase Phase 2
Start date October 31, 2012
Completion date September 12, 2023

See also
  Status Clinical Trial Phase
Completed NCT02057185 - Occupational Status and Hematological Disease
Active, not recruiting NCT02979522 - A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00540007 - Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Completed NCT02378337 - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality N/A
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Phase 1
Completed NCT00388349 - Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Phase 2
Recruiting NCT05255601 - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04998331 - A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Completed NCT02389101 - Molecular and Whole-body MR Imaging in Lymphomas N/A
Completed NCT00871702 - Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Phase 1
Recruiting NCT02589548 - Brazilian Prospective Hodgkin Lymphoma Registry
Completed NCT00398411 - Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Phase 3
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Terminated NCT00225173 - Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease Phase 2
Recruiting NCT06093334 - Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD N/A